Publicaciones en las que colabora con José Manuel García Pinilla (17)

2024

  1. Design and baseline characteristics of SALT-HF trial: hypertonic saline therapy in ambulatory heart failure

    ESC Heart Failure, Vol. 11, Núm. 3, pp. 1767-1776

  2. Efficacy and safety of hypertonic saline therapy in ambulatory patients with heart failure: The SALT-HF trial

    European Journal of Heart Failure, Vol. 26, Núm. 10, pp. 2118-2128

  3. Prevalence and clinical profile of kidney disease in patients with chronic heart failure. Insights from the Spanish cardiorenal registry

    Revista espanola de cardiologia (English ed.), Vol. 77, Núm. 1, pp. 50-59

2023

  1. Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 9, Núm. 1, pp. 42-53

  2. Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction

    Scientific Reports, Vol. 13, Núm. 1

  3. Early glomerular filtration rate decline is associated with hemoglobin rise following dapagliflozin initiation in heart failure with reduced ejection fraction

    Revista Espanola de Cardiologia, Vol. 76, Núm. 10, pp. 783-792

  4. Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study

    European Journal of Heart Failure, Vol. 25, Núm. 8, pp. 1352-1360

  5. Prevalence and clinical profile of kidney disease in patients with chronic heart failure. Insights from the Spanish cardiorenal registry

    Revista Espanola de Cardiologia

  6. Sex differences in Cardiorenal Syndrome: Insights from CARDIOREN Registry

    Current Heart Failure Reports, Vol. 20, Núm. 3, pp. 157-167

  7. Short-Term Changes in Peak VO2 After Initiation of Dapagliflozin in Heart Failure Across Iron Status

    JACC: Heart Failure, Vol. 11, Núm. 11, pp. 1611-1622

  8. Short-term Changes in Hemoglobin and Changes in Functional Status, Quality of Life and Natriuretic Peptides After Initiation of Dapagliflozin in Heart Failure With Reduced Ejection Fraction

    Journal of Cardiac Failure, Vol. 29, Núm. 5, pp. 849-854

2022

  1. Key factors for optimal care models for heart failure. An integrative and multidisciplinary approach

    REC: CardioClinics, Vol. 57, Núm. 1, pp. 24-38

  2. Recommendations to develop Care Models for patients with Heart Failure (MAIC Project) from macromanagement

    Journal of Healthcare Quality Research, Vol. 37, Núm. 2, pp. 100-109

  3. Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2): a randomized clinical trial

    European Journal of Heart Failure, Vol. 24, Núm. 10, pp. 1816-1826

2021

  1. Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & Myocarditis registry

    ESC Heart Failure, Vol. 8, Núm. 1, pp. 95-105

2020

  1. Study design of Heart failure Events reduction with Remote Monitoring and eHealth Support (HERMeS)

    ESC Heart Failure, Vol. 7, Núm. 6, pp. 4448-4457

2018

  1. Genetic Etiology for Alcohol-Induced Cardiac Toxicity

    Journal of the American College of Cardiology, Vol. 71, Núm. 20, pp. 2293-2302